Bellevue Healthcare Trust: China and the funding malaise

Bellevue Healthcare Trust (BBH) fund manager, Paul Major, discusses the significant advancements China has made in healthcare innovation, particularly in the context of clinical trials and drug development. He highlights the challenges faced by Western biotechnology companies due to China's rapid progress and the implications for investment in early-stage companies. Major emphasizes the current dysfunction in the investment landscape and the need for a reevaluation of strategies to navigate the future of biotechnology investment.